
Opinion|Videos|November 29, 2023
Momelotinib in MF: Data from the SIMPLIFY-1 Trial
Author(s)Anthony Hunter, MD
The SIMPLIFY-1 trial investigated the use of momelotinib in JAK inhibitor-naive patients with myelofibrosis, primarily symptomatic with spleen enlargement, hepatomegaly, or anemia; results showed momelotinib led to improved transfusion independence, reduced transfusion burden, and decreased anemia compared to ruxolitinib.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Selinexor Plus Ruxolitinib Improves Spleen Responses, Shows OS Signal in Frontline Myelofibrosis
2
FDA Approves Adjuvant Belzutifan Plus Pembro for Kidney Cancer
3
Generic Larotrectinib Capsules Gain Tentative FDA Approval
4
Dr Hamilton on Tucatinib Maintenance Efficacy in HER2+ Breast Cancer
5




































